HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IKZF3 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-IKZF3.
IKZF3 / AIOLOS Antibody (aa1-301, clone OTI2B9)
Primary AntibodyLSBio Guarantee
| Antibody: | Mouse Monoclonal |
| Applications: | Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot |
| Reactivity: | Human |
| Format: | Liquid |
$443.00each
Catalog Number: LS-C339163-100
Catalog Number: LS-C339163
For bulk orders or custom formulations:
Request a QuoteOverview
- Description
- AIOLOS antibody LS-C339163 is an unconjugated mouse monoclonal antibody to human AIOLOS (IKZF3) (aa1-301). Validated for IHC and WB. Cited in 1 publication.
- Application
- IHC, IHC-P, WB
- Reactivity
- Hu
- Intended Use
- Research Use Only
- Guarantees
- This antibody carries the LSBio 100% Guarantee. ✓
- Category
- Antibodies > Primary Antibodies > Monoclonal Antibodies
- Alternative Names
- AIO | AIOLOS | IKZF3 | Zinc finger protein Aiolos | ZNFN1A3
- Recommended Dilution: IHC-P
- 1:150
- Recommended Dilution: WB
- 1:500
- UniProt Number
- Q9UKT9
- NCBI GenBank
- NM_012481 | NP_036613.2
- SwissProt
- Q9UKT9
Target
- Target
- Human IKZF3 / AIOLOS
- Antigen Species
- Human
- Epitope
- Human IKZF3 / AIOLOS
- Gene Name
- IKZF3
Antibody
- Host Species
- Mouse
- Clonality
- Monoclonal
- Clone
- OTI2B9
- Isotype
- IgG1
Immunogen
- Immunogen
- Human recombinant protein fragment corresponding to amino acids 1-301 of human IKZF3 (NP_036613) produced in E. coli.
- Immunogen Type
- Recombinant Protein Fragment
Format
- Conjugate/Label
- Unconjugated
- Format
- Liquid
- Formulation
- PBS, pH 7.3, 0.02% Sodium Azide, 50% Glycerol, 1% BSA
- Concentration
- 1 mg/mL
- Volume
- 100 Microliter
- Preservative
- Yes
- Purification Method
- Affinity Purified
Storage & Handling
- Storage Conditions
- Store at -20°C. Avoid freeze-thaw cycles.
- Recommended Storage Buffer
- PBS
IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. Heo MH, Park HY, Ko YH, Kim WS, Kim SJ. Journal of Cancer. 2017;8:1018-1024. PubMed: 28529614 PMC: PMC5436254